Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04933929
Other study ID # 2020-A02168-31
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 27, 2020
Est. completion date July 1, 2021

Study information

Verified date February 2023
Source Gérond'if
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The principal aim of this interventional, multicentre study is to compare the impact of a follow-up by monthly telephone dietetic consultations, started 3 months after discharge from hospital, for a period of 3 months, on the energy intake in patients elderly people recently hospitalized for Coronavirus disease 2019 (Covid-19), Coronavirus disease Positive group "Covid (+)", or not, Coronavirus disease Negative group"Covid (-)". The main outcome measure is to compare the total energy intake at 6 months, after 3 months of dietary consultations, between Coronavirus disease Positive group "Covid (+)" and Coronavirus disease negative group "Covid (-)".


Description:

This study consists of nutritional monitoring after hospitalization, carried out by dieticians. Consultations are done remotely, by phone only. Eligible subjects are included, either upon discharge from hospital or within 3 months (at the latest) following their hospitalization. 135 subjects will be included, 50% will be included in Coronavirus disease Positive group "Covid (+)" and 50% in the Coronavirus desease negative group "Covid (-)" . The following data will be collected - At Inclusion (D0): Average length of hospital stay, medical diagnoses, severity of hospital stay, autonomy and dependency scores, albumin and body mass index (BMI). - At M3, M4, M5 and M6: Dietary monitoring data, patient's vital status and dependency scores.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date July 1, 2021
Est. primary completion date April 22, 2021
Accepts healthy volunteers No
Gender All
Age group 75 Years and older
Eligibility Inclusion Criteria: - Patient hospitalized or having been hospitalized in acute geriatrics - Living at home 3 months after hospitalization in acute geriatrics - Having a good understanding of the French language - Being able to understand the study information and participate in telephone follow-up - Having read the information notice and agreeing to participate in the study - For the Covid (+) group: hospitalized for Covid-19 (diagnostic confirmation by positive RT-PCR) - For the Covid group (-): hospitalized for any other reason (negative RT-PCR) Exclusion Criteria: - Patient refusing to participate in the study - Subject to a legal protection measure (curatorship, guardianship or safeguard of justice) - With cognitive impairment making it impossible to understand the study protocol and express consent.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Post-hospitalization nutritional monitoring
Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs & Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .

Locations

Country Name City State
France Geriatric Department, Bichat, Beaujon and Bretonneau hospitals Paris IIe-de-France

Sponsors (1)

Lead Sponsor Collaborator
Gérond'if

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of total energy requirements, after 3 months of dietary consultations, between Covid (+) and Covid (-) groups. A 30 to 40 minute telephone survey by a dietitian, with:
the reminder of food intake over 24 hours, estimation of the weight of each food and quantification in kcal / day and grams of protein / day.
This assessment of food intake will be followed by nutritional advice adapted to the severity of undernutrition, spontaneous food intake, the subject's tastes and dislikes, and the possibilities of preparing the necessary dishes and textures.
6 months
Secondary Assessment of the degree of patient dependence according "Index of Independence in Activities of Daily Living" KATZ scale This is a measurement of the subject's ability to perform activities of daily living independently without including minimum and maximum values At inclusion
Secondary Assessment of patient's level of dependence through an appreciation of instrumental activities of daily living according Lawton scale Assessment of older people: Self-maintaining and instrumental activities of daily living without including minimum and maximum values At inclusion
Secondary Comparison of weight variation by measuring the Body Mass Index (BMI) 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04768998 - Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3
Terminated NCT04940871 - Study to Assess the Efficacy and Safety of Favipiravir-HU Phase 2
Completed NCT04588363 - COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Completed NCT05249816 - Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine Phase 3
Recruiting NCT04863547 - Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection
Terminated NCT04389840 - Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure Phase 2/Phase 3
Completed NCT04725084 - Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Completed NCT04851821 - The Effectiveness of Phytotherapy in SARS-COV2(COVID-19) Phase 1
Withdrawn NCT05545319 - A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 Phase 2
Terminated NCT04391309 - COVID-19 and Anti-CD14 Treatment Trial Phase 2
Completed NCT04343261 - Convalescent Plasma in the Treatment of COVID 19 Phase 2